Direkt zum Inhalt
Merck

Topical tranexamic acid reduces transfusion rates in total hip and knee arthroplasty.

The Journal of arthroplasty (2013-10-08)
Julian Gilbody, Herman S Dhotar, Anthony V Perruccio, J Roderick Davey
ZUSAMMENFASSUNG

The efficaciousness of topical tranexamic acid use at the end of knee arthroplasty surgery to reduce blood loss and transfusion requirements has previously been shown. The aim of this study was to retrospectively assess the effectiveness of topical tranexamic acid use, comparing 155 patients undergoing hip and knee arthroplasty surgery in which tranexamic acid was routinely used, to a group of 149 patients from a similar time frame prior to the introduction of tranexamic acid use. The transfusion rate fell from 19.3% to 2.3% for hip arthroplasty patients and from 13.1% to 0% for knee arthroplasty patients; these differences were significant. We also found significant reductions in haemoglobin loss, blood loss and length of stay of 8 g/L, 244 mL and 1.0 days respectively for hip arthroplasties and 15 g/L, 527 mL and 1.2 days respectively for knee arthroplasties following the introduction of tranexamic acid.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Trans-4-(Aminomethyl)cyclohexancarboxylsäure, 97%
USP
Tranexamsäure, United States Pharmacopeia (USP) Reference Standard
Tranexamsäure, European Pharmacopoeia (EP) Reference Standard